ParkinsonCanadaV1, Main, Exploration, bibRecord, 003585

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

Identifieur interne : 003585 ( Main/Exploration ); précédent : 003584; suivant : 003586

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

Auteurs : R. De La Fuente-Fernandez [Canada] ; P. K. Pal [Canada] ; F. J. G. Vingerhoets [Canada] ; A. Kishore [Canada] ; M. Schulzer [Canada] ; E. K. Mak [Canada] ; T. J. Ruth [Canada] ; B. J. Snow [Canada] ; D. B. Calne [Canada] ; A. J. Stoessl [Canada]

Source :

Journal of neural transmission [ 0300-9564 ] ; 2000.

RBID : Pascal:00-0162255

Descripteurs français

Pascal (Inist)
- Dopamine, Présynaptique, Tomoscintigraphie, Voie nigrostriatale, Fluctuation, Motricité, Parkinson maladie, Idiopathique, Homme.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiparkinson Agents (administration & dosage), Dihydroxyphenylalanine (analogs & derivatives), Dihydroxyphenylalanine (pharmacokinetics), Dopamine, Dopamine (metabolism), Emission tomography, Female, Fluctuations, Fluorine Radioisotopes (pharmacokinetics), Human, Humans, Idiopathic, Levodopa (administration & dosage), Male, Middle Aged, Motor Neurons (metabolism), Motricity, Movement Disorders (diagnostic imaging), Movement Disorders (drug therapy), Movement Disorders (metabolism), Nigrostriatal pathway, Parkinson Disease (diagnostic imaging), Parkinson Disease (drug therapy), Parkinson Disease (metabolism), Parkinson disease, Presynaptic, Presynaptic Terminals (metabolism), Substantia Nigra (cytology), Substantia Nigra (metabolism), Tomography, Emission-Computed.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , analogs & derivatives : Dihydroxyphenylalanine.
- chemical , metabolism : Dopamine.
- chemical , pharmacokinetics : Dihydroxyphenylalanine, Fluorine Radioisotopes.
- cytology : Substantia Nigra.
- diagnostic imaging : Movement Disorders, Parkinson Disease.
- drug therapy : Movement Disorders, Parkinson Disease.
- metabolism : Motor Neurons, Movement Disorders, Parkinson Disease, Presynaptic Terminals, Substantia Nigra.
- Female, Humans, Male, Middle Aged, Tomography, Emission-Computed.

Abstract

We used [¹⁸F]6-fluorodopa (FD) positron emission tomography (PET) to examine the severity of nigrostriatal dopaminergic dysfunction in 67 patients with Idiopathic Parkinsonism (IP), 52 with fluctuations and 15 with a stable response to levodopa. FD uptake (Ki) was reduced by 12% in the caudate (p = 0.08) and by 28% in the putamen (p = 0.0004) of patients with fluctuations compared to those with a stable response. However, there was considerable overlap of FD Ki values between the two groups. The fluctuators had a longer symptom duration (11.6 ± 5.7 years) than the patients with a stable response to levodopa (4.3 ± 2.4 years; p < 0.0001) and the age of onset of symptoms was earlier in the fluctuators (43.9 ± 8.9 versus 54.1 ± 10.4; p = 0.0004). Similar reductions in FD Ki in the fluctuators persisted following adjustment for these variables (7.5% in the caudate and 26% in the putamen; p = n.s. and 0.007, respectively). When smaller groups (n = 15 each) were matched for duration of symptoms, the reduction in caudate Ki in the fluctuators was only 1.9% (p = n.s.), but there was still a 24% reduction in putamen Ki (p = 0.05). These findings suggest that fluctuators and non-fluctuators may differ in the severity of their nigrostriatal damage and provide modest support for the hypothesis that fluctuations may in part reflect altered "buffering' capacity of dopaminergic nerve terminals. However, the considerable overlap between groups suggests that other factors such as altered postsynaptic mechanisms and/or increased turnover of dopamine may make a substantial contribution to the development of motor fluctuations.

Affiliations:

Canada

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations</title>
<author><name sortKey="De La Fuente Fernandez, R" sort="De La Fuente Fernandez, R" uniqKey="De La Fuente Fernandez R" first="R." last="De La Fuente-Fernandez">R. De La Fuente-Fernandez</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pal, P K" sort="Pal, P K" uniqKey="Pal P" first="P. K." last="Pal">P. K. Pal</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vingerhoets, F J G" sort="Vingerhoets, F J G" uniqKey="Vingerhoets F" first="F. J. G." last="Vingerhoets">F. J. G. Vingerhoets</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kishore, A" sort="Kishore, A" uniqKey="Kishore A" first="A." last="Kishore">A. Kishore</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M." last="Schulzer">M. Schulzer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mak, E K" sort="Mak, E K" uniqKey="Mak E" first="E. K." last="Mak">E. K. Mak</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T. J." last="Ruth">T. J. Ruth</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0162255</idno>
<date when="2000">2000</date>
<idno type="stanalyst">PASCAL 00-0162255 INIST</idno>
<idno type="RBID">Pascal:00-0162255</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D12</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000012</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000B92</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000B92</idno>
<idno type="wicri:doubleKey">0300-9564:2000:De La Fuente Fernandez R:evidence:for:impaired</idno>
<idno type="wicri:Area/Main/Merge">003B26</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:10809403</idno>
<idno type="wicri:Area/PubMed/Corpus">001669</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001669</idno>
<idno type="wicri:Area/PubMed/Curation">001669</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001669</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001669</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001669</idno>
<idno type="wicri:Area/Ncbi/Merge">000098</idno>
<idno type="wicri:Area/Ncbi/Curation">000098</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000098</idno>
<idno type="wicri:doubleKey">0300-9564:2000:De La Fuente Fernandez R:evidence:for:impaired</idno>
<idno type="wicri:Area/Main/Merge">003890</idno>
<idno type="wicri:Area/Main/Curation">003585</idno>
<idno type="wicri:Area/Main/Exploration">003585</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations</title>
<author><name sortKey="De La Fuente Fernandez, R" sort="De La Fuente Fernandez, R" uniqKey="De La Fuente Fernandez R" first="R." last="De La Fuente-Fernandez">R. De La Fuente-Fernandez</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Pal, P K" sort="Pal, P K" uniqKey="Pal P" first="P. K." last="Pal">P. K. Pal</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Vingerhoets, F J G" sort="Vingerhoets, F J G" uniqKey="Vingerhoets F" first="F. J. G." last="Vingerhoets">F. J. G. Vingerhoets</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kishore, A" sort="Kishore, A" uniqKey="Kishore A" first="A." last="Kishore">A. Kishore</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M." last="Schulzer">M. Schulzer</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Mak, E K" sort="Mak, E K" uniqKey="Mak E" first="E. K." last="Mak">E. K. Mak</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T. J." last="Ruth">T. J. Ruth</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Neurodegenerative Disorders Centre, Vancouver Hospital and Health Sciences Centre</s1>
<s2>Vancouver, BC</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>Vancouver, BC</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of neural transmission</title>
<title level="j" type="abbreviated">J. neural transm.</title>
<idno type="ISSN">0300-9564</idno>
<imprint><date when="2000">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of neural transmission</title>
<title level="j" type="abbreviated">J. neural transm.</title>
<idno type="ISSN">0300-9564</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiparkinson Agents (administration & dosage)</term>
<term>Dihydroxyphenylalanine (analogs & derivatives)</term>
<term>Dihydroxyphenylalanine (pharmacokinetics)</term>
<term>Dopamine</term>
<term>Dopamine (metabolism)</term>
<term>Emission tomography</term>
<term>Female</term>
<term>Fluctuations</term>
<term>Fluorine Radioisotopes (pharmacokinetics)</term>
<term>Human</term>
<term>Humans</term>
<term>Idiopathic</term>
<term>Levodopa (administration & dosage)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Motor Neurons (metabolism)</term>
<term>Motricity</term>
<term>Movement Disorders (diagnostic imaging)</term>
<term>Movement Disorders (drug therapy)</term>
<term>Movement Disorders (metabolism)</term>
<term>Nigrostriatal pathway</term>
<term>Parkinson Disease (diagnostic imaging)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson disease</term>
<term>Presynaptic</term>
<term>Presynaptic Terminals (metabolism)</term>
<term>Substantia Nigra (cytology)</term>
<term>Substantia Nigra (metabolism)</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Dihydroxyphenylalanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacokinetics" xml:lang="en"><term>Dihydroxyphenylalanine</term>
<term>Fluorine Radioisotopes</term>
</keywords>
<keywords scheme="MESH" qualifier="cytology" xml:lang="en"><term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnostic imaging" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Movement Disorders</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Motor Neurons</term>
<term>Movement Disorders</term>
<term>Parkinson Disease</term>
<term>Presynaptic Terminals</term>
<term>Substantia Nigra</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Tomography, Emission-Computed</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term>
<term>Présynaptique</term>
<term>Tomoscintigraphie</term>
<term>Voie nigrostriatale</term>
<term>Fluctuation</term>
<term>Motricité</term>
<term>Parkinson maladie</term>
<term>Idiopathique</term>
<term>Homme</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We used [<sup>18</sup>
F]6-fluorodopa (FD) positron emission tomography (PET) to examine the severity of nigrostriatal dopaminergic dysfunction in 67 patients with Idiopathic Parkinsonism (IP), 52 with fluctuations and 15 with a stable response to levodopa. FD uptake (Ki) was reduced by 12% in the caudate (p = 0.08) and by 28% in the putamen (p = 0.0004) of patients with fluctuations compared to those with a stable response. However, there was considerable overlap of FD Ki values between the two groups. The fluctuators had a longer symptom duration (11.6 ± 5.7 years) than the patients with a stable response to levodopa (4.3 ± 2.4 years; p < 0.0001) and the age of onset of symptoms was earlier in the fluctuators (43.9 ± 8.9 versus 54.1 ± 10.4; p = 0.0004). Similar reductions in FD Ki in the fluctuators persisted following adjustment for these variables (7.5% in the caudate and 26% in the putamen; p = n.s. and 0.007, respectively). When smaller groups (n = 15 each) were matched for duration of symptoms, the reduction in caudate Ki in the fluctuators was only 1.9% (p = n.s.), but there was still a 24% reduction in putamen Ki (p = 0.05). These findings suggest that fluctuators and non-fluctuators may differ in the severity of their nigrostriatal damage and provide modest support for the hypothesis that fluctuations may in part reflect altered "buffering' capacity of dopaminergic nerve terminals. However, the considerable overlap between groups suggests that other factors such as altered postsynaptic mechanisms and/or increased turnover of dopamine may make a substantial contribution to the development of motor fluctuations.</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
</country>
</list>
<tree><country name="Canada"><noRegion><name sortKey="De La Fuente Fernandez, R" sort="De La Fuente Fernandez, R" uniqKey="De La Fuente Fernandez R" first="R." last="De La Fuente-Fernandez">R. De La Fuente-Fernandez</name>
</noRegion>
<name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D. B." last="Calne">D. B. Calne</name>
<name sortKey="Kishore, A" sort="Kishore, A" uniqKey="Kishore A" first="A." last="Kishore">A. Kishore</name>
<name sortKey="Mak, E K" sort="Mak, E K" uniqKey="Mak E" first="E. K." last="Mak">E. K. Mak</name>
<name sortKey="Pal, P K" sort="Pal, P K" uniqKey="Pal P" first="P. K." last="Pal">P. K. Pal</name>
<name sortKey="Ruth, T J" sort="Ruth, T J" uniqKey="Ruth T" first="T. J." last="Ruth">T. J. Ruth</name>
<name sortKey="Schulzer, M" sort="Schulzer, M" uniqKey="Schulzer M" first="M." last="Schulzer">M. Schulzer</name>
<name sortKey="Snow, B J" sort="Snow, B J" uniqKey="Snow B" first="B. J." last="Snow">B. J. Snow</name>
<name sortKey="Stoessl, A J" sort="Stoessl, A J" uniqKey="Stoessl A" first="A. J." last="Stoessl">A. J. Stoessl</name>
<name sortKey="Vingerhoets, F J G" sort="Vingerhoets, F J G" uniqKey="Vingerhoets F" first="F. J. G." last="Vingerhoets">F. J. G. Vingerhoets</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003585 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003585 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:00-0162255
   |texte=   Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations
}}

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

La maladie de Parkinson au Canada (serveur d'exploration)

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.